Posted by Michael Wonder on 22 Aug 2025
Leqvio advances toward broader access with agreement between Novartis and the pan-Canadian Pharmaceutical Alliance
21 August 2025 - Eligible Canadian patients with heterozygous familial hypercholesterolaemia are one step closer to publicly funded access to cholesterol lowering treatment.
Novartis Pharmaceuticals Canada is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance for the public reimbursement of Leqvio (inclisiran) for the treatment of adults with heterozygous familial hypercholesterolaemia, a genetic condition characterised by elevated levels of low-density lipoprotein cholesterol, significantly increasing the risk of early cardiovascular events such as heart attack and stroke.
